Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Malignant Disease × Etoposide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 28 Leukemia, Myeloid, Acute 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Leukemia 23 Lymphoma 22 Small Cell Lung Carcinoma 20 Burkitt Lymphoma 19 Lymphoma, Non-Hodgkin 18 Lung Neoplasms 13 Recurrence 12 Neuroblastoma 12 Lymphoma, Mantle-Cell 12 Leukemia, Lymphocytic, Chronic, B-Cell 12 Congenital Abnormalities 12 Myelodysplastic Syndromes 11 Lymphoma, Follicular 11 Brain Neoplasms 10 Hodgkin Disease 9 Carcinoma, Non-Small-Cell Lung 9 Lymphoma, Large-Cell, Immunoblastic 8 Lymphoma, B-Cell, Marginal Zone 8 Leukemia, Myeloid, Accelerated Phase 8 Leukemia, Monocytic, Acute 8 Leukemia, Megakaryoblastic, Acute 8 Leukemia, Erythroblastic, Acute 8 Blast Crisis 8 Sarcoma 7 Neoplasms 7 Myeloproliferative Disorders 7 Multiple Myeloma 7

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡